Q-omics provides the consensus-scored ZNF382 profile across patient tissues and cancer cell-line models. ZNF382 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF382 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, ZNF382 RNA expression shows 19,766 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where ZNF382 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF382 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF382 survival associations across molecular data types. ZNF382 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF382 RNA expression–survival associations across cancer types. High ZNF382 expression shows unfavorable associations in LUSC and LGG, but favorable associations in HNSC, UCS, PAAD and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF382 RNA expression.
This table summarizes ZNF382 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF382. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF382 shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, BRCA, CHOL and KIRP. The THCA box plot shows higher ZNF382 RNA expression in normal versus tumor tissue (log2 FC = −0.430, t-test p < 0.001).
This table shows molecular features associated with ZNF382 in patient tissues and cancer cell lines. In patient samples, ZNF382 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF382 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
